A Flexible, Thermostable Nanostructured Lipid Carrier Platform for RNA Vaccine Delivery

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2022 Mar 21

PMID 35308783

Authors

Alana Gerhardt

Emily Voigt

Michelle Archer

Sierra Reed

Elise Larson

Neal Van Hoeven

Ryan Kramer

Christopher Fox

Corey Casper

Affiliations

Soon will be listed here.

Abstract

Current RNA vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited by instability of both the RNA and the lipid nanoparticle delivery system, requiring storage at -20°C or -70°C and compromising universally accessible vaccine distribution. This study demonstrates the thermostability and adaptability of a nanostructured lipid carrier (NLC) delivery system for RNA vaccines that has the potential to address these concerns. Liquid NLC alone is stable at refrigerated temperatures for ≥1 year, enabling stockpiling and rapid deployment by point-of-care mixing with any vaccine RNA. Alternatively, NLC complexed with RNA may be readily lyophilized and stored at room temperature for ≥8 months or refrigerated temperature for ≥21 months while still retaining the ability to express protein . The thermostability of this NLC/RNA vaccine delivery platform could significantly improve distribution of current and future pandemic response vaccines, particularly in low-resource settings.

Citing Articles

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.

Leong K, Tham S, Poh C Virol J. 2025; 22(1):71.

PMID: 40075519 PMC: 11900334. DOI: 10.1186/s12985-025-02645-6.

Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.

Christodoulou M, Papagiannis D Vaccines (Basel). 2025; 13(2).

PMID: 40006698 PMC: 11861857. DOI: 10.3390/vaccines13020151.

Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines.

Chentoufi A, Ulmer J, BenMohamed L Vaccines (Basel). 2025; 13(1).

PMID: 39852809 PMC: 11769099. DOI: 10.3390/vaccines13010030.

Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.

Lykins W, Pollet J, White J, Keegan B, Versteeg L, Strych U Front Immunol. 2024; 15:1480976.

PMID: 39737197 PMC: 11683073. DOI: 10.3389/fimmu.2024.1480976.

Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability.

Gulati G, Simpson A, MacMillen Z, Krieger K, Sharma S, Erasmus J J Control Release. 2024; 377:81-92.

PMID: 39547422 PMC: 11663110. DOI: 10.1016/j.jconrel.2024.11.023.

References

Hassett K, Benenato K, Jacquinet E, Lee A, Woods A, Yuzhakov O . Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019; 15:1-11. PMC: 6383180. DOI: 10.1016/j.omtn.2019.01.013. View

Franze S, Selmin F, Samaritani E, Minghetti P, Cilurzo F . Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging. Pharmaceutics. 2018; 10(3). PMC: 6161153. DOI: 10.3390/pharmaceutics10030139. View

Blakney A, McKay P, Yus B, Aldon Y, Shattock R . Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019; 26(9):363-372. PMC: 6760535. DOI: 10.1038/s41434-019-0095-2. View

Brito L, Chan M, Shaw C, Hekele A, Carsillo T, Schaefer M . A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014; 22(12):2118-2129. PMC: 4429691. DOI: 10.1038/mt.2014.133. View

Deering R, Kommareddy S, Ulmer J, Brito L, Geall A . Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv. 2014; 11(6):885-99. DOI: 10.1517/17425247.2014.901308. View

Kramer R, Archer M, Orr M, Cauwelaert N, Beebe E, Huang P . Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach. Int J Nanomedicine. 2018; 13:3689-3711. PMC: 6028350. DOI: 10.2147/IJN.S159839. View

Kumru O, Joshi S, Smith D, Middaugh C, Prusik T, Volkin D . Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 2014; 42(5):237-59. DOI: 10.1016/j.biologicals.2014.05.007. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Viger-Gravel J, Schantz A, Pinon A, Rossini A, Schantz S, Emsley L . Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR Spectroscopy. J Phys Chem B. 2018; 122(7):2073-2081. DOI: 10.1021/acs.jpcb.7b10795. View

10.

Guan S, Rosenecker J . Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017; 24(3):133-143. DOI: 10.1038/gt.2017.5. View

11.

Jones K, Drane D, Gowans E . Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques. 2007; 43(5):675-81. PMC: 4526277. DOI: 10.2144/000112593. View

12.

Whitehead K, Langer R, Anderson D . Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129-38. PMC: 7097568. DOI: 10.1038/nrd2742. View

13.

Erasmus J, Khandhar A, Guderian J, Granger B, Archer J, Archer M . A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. Mol Ther. 2018; 26(10):2507-2522. PMC: 6171036. DOI: 10.1016/j.ymthe.2018.07.010. View

14.

Wang Y, Grainger D . Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments. Adv Drug Deliv Rev. 2019; 151-152:56-71. DOI: 10.1016/j.addr.2019.03.003. View

15.

Sahin U, Kariko K, Tureci O . mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014; 13(10):759-80. DOI: 10.1038/nrd4278. View

16.

Tam Y, Chen S, Cullis P . Advances in Lipid Nanoparticles for siRNA Delivery. Pharmaceutics. 2013; 5(3):498-507. PMC: 3836621. DOI: 10.3390/pharmaceutics5030498. View

17.

Reichmuth A, Oberli M, Jaklenec A, Langer R, Blankschtein D . mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016; 7(5):319-34. PMC: 5439223. DOI: 10.4155/tde-2016-0006. View

18.

Alberer M, Gnad-Vogt U, Hong H, Mehr K, Backert L, Finak G . Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017; 390(10101):1511-1520. DOI: 10.1016/S0140-6736(17)31665-3. View

19.

Leung A, Hafez I, Baoukina S, Belliveau N, Zhigaltsev I, Afshinmanesh E . Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces. 2012; 116(34):18440-18450. PMC: 3434764. DOI: 10.1021/jp303267y. View

20.

Stitz L, Vogel A, Schnee M, Voss D, Rauch S, Mutzke T . A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017; 11(12):e0006108. PMC: 5737050. DOI: 10.1371/journal.pntd.0006108. View